ARTICLE | Distillery Therapeutics
Cancer
February 6, 2018 5:08 PM UTC
Cell culture and mouse studies suggest combining paclitaxel-loaded nanoparticles and the multikinase inhibitor Vargatef nintedanib could help treat p53-deficient endometrial cancer. In a p53-deficient human endometrial cancer cell line, paclitaxel-loaded nanoparticles plus Vargatef decreased viability compared with no treatment. In a xenograft mouse model of p53-deficient endometrial cancer, the combination treatment decreased tumor volume and increased survival. Next steps include optimizing the nanoparticle formulation for efficacy...
BCIQ Company Profiles